Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 08, 2025 (GLOBE NEWSWIRE) — Primo Biotechnology (“Primo”) today announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear medicine production. The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), SHINE’s high-purity therapeutic isotope, to TRead More